Comparative Pharmacology
Head-to-head clinical analysis: OSMOVIST 190 versus UROVIST SODIUM 300.
Peer-Reviewed Evidence
Head-to-head clinical analysis: OSMOVIST 190 versus UROVIST SODIUM 300.
OSMOVIST 190 vs UROVIST SODIUM 300
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Iodinated contrast media with high osmolality, providing radiographic contrast by attenuating X-rays, primarily due to iodine content.
Iodinated contrast agent that attenuates X-rays, improving visualization of vascular structures and organs during imaging.
Intravenous administration of 0.1-0.3 mL/kg (0.19-0.57 mg iodine/kg) for adults; may repeat as needed. Maximum total dose 1.5 mL/kg.
Intravenous injection of 50-100 mL for contrast imaging, typically a single dose of 300 mg iodine/mL.
None Documented
None Documented
Terminal elimination half-life approximately 110 minutes. In renal impairment, half-life is prolonged, requiring dose adjustment.
Terminal elimination half-life is approximately 2 hours in patients with normal renal function (GFR >90 mL/min). In renal impairment, half-life may be prolonged up to 10 hours or more, correlating with decreased GFR.
Primarily renal (glomerular filtration). Excreted unchanged in urine, with less than 2% biliary/fecal excretion.
Primarily renal (glomerular filtration), with >90% of the administered dose excreted unchanged in urine within 24 hours. Biliary/fecal excretion is negligible (<5%).
Category C
Category C
Radiographic Contrast Agent
Radiographic Contrast Agent